Skip Navigation LinksHome > July 2006 - Volume 1 - Issue 6 > Prostacyclin in Lung Cancer
Text sizing:
Journal of Thoracic Oncology:
Gene or Pathway of the Month

Prostacyclin in Lung Cancer

Keith, Robert L. MD*†; Geraci, Mark W. MD†

Free Access
Article Outline
Collapse Box

Author Information

*Department of Medicine, Denver VA Medical Center; †Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado

Address for correspondence: Robert L. Keith, M.D., Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, Denver VA Medical Center, 1055 Clermont St. Box 111A, Denver, CO 80220.

Prostacyclin is a naturally occurring eicosanoid that possesses anti-inflammatory and anti-metastatic properties and has a suppressive role in tumor growth.1 Prostacyclin synthase (PGIS) is the final committed enzymatic step in the pathway of PGI2 production, occurring at a branch point where substrate can be directed toward either PGI2, thromboxane A2 (TxA2), or prostaglandin E2 (PGE2) (Figure 1). Eicosanoid production and balance is proving pivotal in lung tumorigenesis.

Figure 1
Figure 1
Image Tools
Back to Top | Article Outline


Prostacyclin (PGI2) is a lipid mediator derived through the cyclo-oxygenase (COX) pathway. The cascade leading to the production of PGI2 is shown in Figure 1. Phospholipase A2 (PLA2) cleaves arachidonic acid from lipid bilayers to form free fatty acids. It is generally believed that rate-limiting steps in the arachidonic acid cascade occur at both arachidonic acid formation and the formation of prostaglandin H2 (PGH2) by prostaglandin H2 synthases (more commonly known as COX-1 and COX-2).2 There are two PGH synthase isozymes called COX-1 and COX-2. Each enzyme is coded by a different gene and is under separate regulatory control.3

PGI2 is one of the main products of arachidonic acid in all vascular tissues tested to date.4 Once released from cells, PGI2 acts as an autocrine and paracrine effector to regulate the function of various differentiated cells and platelets. Prostacyclin has many important biologic effects. It is the most potent endogenous inhibitor of platelet aggregation yet discovered,4 and as a product of the vascular wall endothelium and smooth muscle cells, PGI2 produces vasodilation of all vascular beds studied.5 PGI2 also inhibits both proliferation and DNA synthesis in smooth muscle cells.6

Back to Top | Article Outline


As illustrated in Figure 1, there are two documented signaling pathways for prostacyclin. The first is through its well-described membrane receptor (IP), and the second is at the nuclear membrane via the peroxisome-proliferator activated receptors (PPARs).7 The IP is a single canonical cell membrane-specific seven-transmembrane domain G protein-coupled receptor that has been cloned and characterized,8 with ligand binding resulting in G protein activation and stimulation of adenyl cyclase (thereby increasing intracellular cAMP).9 PPARs are members of the nuclear hormone receptor superfamily that act as ligand-activated transcription factors. Three isoforms have been identified: PPARα, γ, and δ–-all of which bind to specific DNA sequences as heterodimers with the retinoic acid X-receptors and regulate gene transcription.10 PPAR expression is increased in lung cancer and may play a critical role in malignant transformation.11 Eicosanoids, like prostacyclin, are ligands for the PPARδ promoter responsive element7 and can modify PPAR activity. Prostacyclin analogues can activate the PPARδ receptor and have been shown to inhibit the growth of A549 non-small cell lung cancer (NSCLC) cell lines.12 PGIS and PGI2 may also affect PPARγ activity. Our laboratory has shown that lung-specific PGIS overexpression results in a nearly twofold induction of PPARγ expression,13 and PPARγ activation by ligands (like the synthetic thiazolidinediones) results in growth arrest of human NSCLC cell lines.14

The regulation of prostacyclin production has been an area of concentrated research, and plasma lipoproteins, TxA2 analogues, vitamin D3, and plant sterols have all been shown to induce in vitro prostacyclin production.15–17 Variations in the PGIS promoter may affect PGI2 synthesis, and the promoter contains highly GC-rich regions and multiple putative AP1 and SP2 transcription factor binding sites.18 Additionally, a variable number of tandem repeats, varying from three to seven base pairs in length, in the proximal promoter have been correlated with low and high pulse pressures in a Japanese cohort.19 PGIS promoter polymorphisms in lung cancer and chronic obstructive pulmonary disease are currently being actively investigated by our group.

Back to Top | Article Outline


Based on its anti-inflammatory and anti-metastatic effects and its suppressive role in tumor growth, we studied prostacyclin as a lung cancer chemopreventive agent. Comparative immunohistochemical analyses of NSCLC and normal human lung tissue focusing on the COX pathway have shown that tumors are typically positive for TxA2 synthase, PGD2 synthase, and PGE2 synthase, but negative for PGIS.20 Gene expression analysis of NSCLC shows that PGIS content in human lung adenocarcinomas (AC) is usually down-regulated while PGES content rises.21 However, a small subset of patients with AC whose lung tumors retained PGIS expression survived significantly longer.21 Furthermore, murine lung tumor cells lines produce more PGE2 and less PGI2 than non-tumorigenic cell lines.22 In preclinical chemoprevention studies, we have shown that selective pulmonary PGIS overexpression protects against murine lung tumorigenesis in a variety of murine tumorigenesis models, including tobacco smoke exposure.13,23 The beneficial effects of PGIS overexpression could be the result of either higher levels of PGI2 or lower levels of PGE2 as a result of depletion of the precursor substrate PGH2. In the multiple carcinogenesis models applied to the PGIS overexpressing animals, elevation of PGI2 (not decreases in PGE2) was consistently required for chemoprevention to occur.

Based on the preclinical studies summarized above, the National Cancer Institute is currently funding the Lung Cancer Biomarker and Chemoprevention Consortium to conduct a multicenter study investigating the use of Iloprost (an oral prostacyclin analogue) for lung cancer chemoprevention.

Back to Top | Article Outline


1. Schirner M, Schneider MR. Inhibition of metastasis by cicaprost in rats with established SMT2A mammary carcinoma growth. Cancer Detect Prev 1997;21:44–50.

2. Marnett LJ, Siedlik PH, Ochs RC, et al. Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom. Mol Pharmacol 1984;26:328–335.

3. Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 1992;267:7991–7994.

4. Bunting S, Gryglewski R, Moncada S, Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins 1976;12:897–913.

5. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978;30:293–331.

6. Libby P, Warner SJ, Friedman GB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1988;81:487–498.

7. Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 2000;97:13275–13280.

8. Namba T, Oida H, Sugimoto Y, et al. cDNA cloning of a mouse prostacyclin receptor: multiple signaling pathways and expression in thymic medulla. J Biol Chem 1994;269:9986–9992.

9. Shaul PW, Kinane B, Farrar MA, Buja LM, Magness RR. Prostacyclin production and mediation of adenylate cyclase activity in the pulmonary artery: alterations after prolonged hypoxia in the rat. J Clin Invest 1991;88:447–455.

10. DiRenzo J, Soderstrom M, Kurokawa R, et al. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol 1997;17:2166–2176.

11. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004;4:61–70.

12. Fukumoto K, Yano Y, Virgona N, et al. Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. FEBS Lett 2006;579:3829–3836.

13. Keith RL, Miller YE, Hudish TM, et al. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 2004;64:5897–5904.

14. Keshamouni VG, Reddy RC, Arenberg DA, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004;23:100–108.

15. Pomerantz KB, Tall AR, Feinmark SJ, Cannon PJ. Stimulation of vascular smooth muscle cell prostacyclin and prostaglandin E2 synthesis by plasma high and low density lipoproteins. Circ Res 1984;54:554–565.

16. Hassid A. Stimulation of prostacyclin synthesis by thromboxane A2-like prostaglandin endoperoxide analogues in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1984;123:21–26.

17. Wakasugi M, Noguchi T, Inoue M, et al. Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells. Prostaglandins 1991;42:127–136.

18. Yokoyama C, Yabuki T, Inoue H, et al. Human gene encoding prostacyclin synthase (PTGIS): genomic organization, chromosomal localization, and promoter activity. Genomics 1996;36:296–304.

19. Iwai N, Katsuya T, Ishikawa K, et al. Human prostacyclin synthase gene and hypertension: the Suita Study. Circulation 1999;100:2231–2236.

20. Ermert L, Dierkes C, Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 2003;9:1604–1610.

21. Stearman RS, Dwyer-Nield L, Zerbe L, et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 2006;167:1763–1775.

22. Dwyer-Nield L, Srebernak MC, Barrett BS, et al. Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic vs. non-tumorigenic mouse lung epithelial cell lines. Carcinogenesis 2006;26:1196–1206.

23. Keith RL, Miller YE, Hoshikawa Y, et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 2002;62:734–740.

Cited By:

This article has been cited 3 time(s).

European Respiratory Journal
High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications
Ocak, S; Sos, ML; Thomas, RK; Massion, PP
European Respiratory Journal, 34(2): 489-506.
European Respiratory Journal
Prostacyclin therapies for the treatment of pulmonary arterial hypertension
Gomberg-Maitland, M; Olschewski, H
European Respiratory Journal, 31(4): 891-901.
Translational Research
The role of prostacyclin in lung cancer
Tennis, MA; Vanscoyk, M; Keith, RL; Winn, RA
Translational Research, 155(2): 57-61.
Back to Top | Article Outline

© 2006International Association for the Study of Lung Cancer


Article Tools



Other Ways to Connect



Visit on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.